Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Cancer Australia"
Count: 127
Selected: 0
| NCT ID | Title |
|---|
| NCT02948543 | Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer | ||
| NCT00850772 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer | ||
| NCT03091764 | Evaluation of a Patient-Reported Symptom Index for NMIBC | ||
| NCT00096408 | Laparoscopic Approach to Cancer of the Endometrium | ||
| NCT00604994 | Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer | ||
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial | ||
| NCT03464942 | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer | ||
| NCT04074460 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study | ||
| NCT05196789 | Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) | ||
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | ||
| NCT01142011 | A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia | ||
| NCT00098995 | Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | ||
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | ||
| NCT01755650 | Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies | ||
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | ||
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT04534725 | COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; | ||
| NCT05666700 | CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study | ||
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | ||
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma | ||
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | ||
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | ||
| NCT02855203 | Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours | ||
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy | ||
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI | ||
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) | ||
| NCT05570227 | Metabolic Phenotypes in Melanoma | ||
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study | ||
| NCT05878288 | Deep sequencIng in Cutaneous Squamous CEll caRciNomas | ||
| NCT05063838 | Perioperative Pharmacogenomic Testing | ||
| NCT03900884 | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | ||
| NCT04801966 | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | ||
| NCT05263700 | FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary | ||
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | ||
| NCT03299660 | Avelumab With Chemoradiation in Locally Advanced Rectal Cancer | ||
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma | ||
| NCT04985721 | A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | ||
| NCT03287427 | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial | ||
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | ||
| NCT04234061 | Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma | ||
| NCT03980171 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | ||
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T | ||
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer | ||
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | ||
| NCT02506556 | Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer | ||
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | ||
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma | ||
| NCT03569072 | High Intensity Functional Image Guided Vmat Lung Evasion |
